文献速递炎症性肠病

抗生素、激素治疗、口服避孕药与长期非甾体抗炎药与炎症性肠病风险的关联:前瞻性城乡流行病学(PURE)研究结果

Associations of Antibiotics, Hormonal Therapies, Oral Contraceptives, and Long-Term NSAIDS With Inflammatory Bowel Disease: Results From the Prospective Urban Rural Epidemiology (PURE) Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-12-15

基于24个国家133,137名20至80岁人群的前瞻性队列研究,中位随访11.0年发生571例新发炎症性肠病(143例克罗恩病,428例溃疡性结肠炎)。基线抗生素使用(aOR 2.81)、激素药物使用(aOR 4.43)、女性口服避孕药使用(aOR 2.17)及长期非甾体抗炎药使用(aOR 5.58)均与新发炎症性肠病风险升高相关。

要点

  • 基线抗生素使用与新发炎症性肠病风险升高相关(aOR 2.81,95%CI 1.67-4.73)。
  • 女性口服避孕药使用与新发炎症性肠病风险升高相关(aOR 2.17,95%CI 1.70-2.77)。
  • 长期非甾体抗炎药使用与新发炎症性肠病风险升高相关(aOR 5.58,95%CI 2.26-13.80)。

核心结论

  • 校正协变量后,抗生素、激素药物、口服避孕药及长期非甾体抗炎药使用与新发炎症性肠病风险升高相关。

研究设计与样本

  • 前瞻性队列研究,纳入24个国家133,137名20至80岁个体,至少每3年进行前瞻性随访。
  • 使用各国验证问卷记录基线和随访期药物使用,评估短期使用(仅基线使用而随访未使用)和长期使用(基线和后续随访均使用)。

主要发现

  • 中位随访11.0年(四分位距9.2-12.2年)期间发生571例新发炎症性肠病,包括143例克罗恩病和428例溃疡性结肠炎。
  • 基线抗生素使用与新发炎症性肠病显著相关(aOR 2.81,95%CI 1.67-4.73,P=.0001)。
  • 基线激素药物使用与新发炎症性肠病显著相关(aOR 4.43,95%CI 1.78-11.01,P=.001)。
  • 女性既往或当前口服避孕药使用与新发炎症性肠病相关(aOR 2.17,95%CI 1.70-2.77,P<.001)。
  • 非甾体抗炎药使用者新发炎症性肠病风险升高(aOR 1.80,95%CI 1.23-2.64,P=.002),主要由长期使用驱动(aOR 5.58,95%CI 2.26-13.80,P<.001)。

关键数值与推荐

  • 所有显著结果在克罗恩病和溃疡性结肠病中方向一致,异质性低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Several medications have been suspected to contribute to the etiology of inflammatory bowel disease (IBD). This study assessed the association between medication use and the risk of developing IBD using the Prospective Urban Rural Epidemiology cohort. METHODS: This was a prospective cohort study of 133,137 individuals between the ages of 20 and 80 from 24 countries. Country-specific validated questionnaires documented baseline and follow-up medication use. Participants were followed up prospectively at least every 3 years. The main outcome was the development of IBD, including Crohn's disease (CD) and ulcerative colitis (UC). Short-term (baseline but not follow-up use) and long-term use (baseline and subsequent follow-up use) were evaluated. Results are presented as adjusted odds ratios (aORs) with 95% CIs. RESULTS: During a median follow-up period of 11.0 years (interquartile range, 9.2-12.2 y), there were 571 incident IBD cases (143 CD and 428 UC). Incident IBD was associated significantly with baseline antibiotic (aOR, 2.81; 95% CI, 1.67-4.73; P = .0001) and hormonal medication use (aOR, 4.43; 95% CI, 1.78-11.01; P = .001). Among females, previous or current oral contraceptive use also was associated with IBD development (aOR, 2.17; 95% CI, 1.70-2.77; P < .001). Nonsteroidal anti-inflammatory drug users also were observed to have increased odds of IBD (aOR, 1.80; 95% CI, 1.23-2.64; P = .002), which was driven by long-term use (aOR, 5.58; 95% CI, 2.26-13.80; P < .001). All significant results were consistent in direction for CD and UC with low heterogeneity. CONCLUSIONS: Antibiotics, hormonal medications, oral contraceptives, and long-term nonsteroidal anti-inflammatory drug use were associated with increased odds of incident IBD after adjustment for covariates.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Narula N, Wong ECL, Pray C, et al. Associations of Antibiotics, Hormonal Therapies, Oral Contraceptives, and Long-Term NSAIDS With Inflammatory Bowel Disease: Results From the Prospective Urban Rural Epidemiology (PURE) Study. Clin Gastroenterol Hepatol. 2022. PMID: 36528284. doi:10.1016/j.cgh.2022.11.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。